Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.40 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.40 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.40 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21269888 | 0.96 | CYP1A2 (0.50) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| SCHEMBL21269018 | 0.96 | CYP1A2 (0.50) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| SCHEMBL21268836 | 0.96 | CYP1A2 (0.50) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| Lithium Ion SCHEMBL21269484 | 0.96 | CYP1A2 (0.50) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| Potassium Ion SCHEMBL21269901 | 0.96 | CYP1A2 (0.50) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| Potassium Ion SCHEMBL21269571 | 0.94 | CYP1A2 (0.48) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| Lithium Ion SCHEMBL21269586 | 0.94 | CYP1A2 (0.48) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| Potassium Ion SCHEMBL21269215 | 0.94 | CYP1A2 (0.48) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| SCHEMBL21269485 | 0.81 | CYP2D6 (0.57) | CYP2D6CYP1A2CYP2C19HIF1AMAPT | |
| SCHEMBL21268837 | 0.81 | CYP2D6 (0.57) | CYP2D6CYP1A2CYP2C19HIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3527616-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION Ltd. (IN) | 2019-08-21 | — | — | EP | claimed |
| EP-3527616-B1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORP LTD (IN) | 2024-02-07 | — | — | EP | disclosed |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | INDIAN OIL CORPORATION LIMITED (IN) | 2021-11-23 | — | — | US | disclosed |
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION LIMITED (IN) | 2019-08-22 | — | — | US | disclosed |
| EP-3527616-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | INDIAN OIL CORPORATION Ltd. (IN) | 2019-08-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256683-A1 | METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS | NUMA1, MNS1, ME1 | GRIN2D 3377/4885GRIN1 1812/4885GRIN2A 2818/4885 |
| US-11180630-B2 | Metal salts of malonic acid as nucleating additives for crystalline thermoplastics | NUMA1, MNS1, ME1 | GRIN2D 3377/4885GRIN1 1812/4885GRIN2A 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.